Dirk Schadendorf, MD - An Evolution in Care for Advanced Melanoma: Exploring the Clinical Implications of Approved and Emerging Anti–LAG-3/PD-1 Combinations

Please visit answersincme.com/ZUU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology and oncology discusses the clinical implications of approved and emerging anti–lymphocyte activation gene-3 (LAG-3)/programmed cell death protein 1 (PD-1) combinations in advanced melanoma. Upon completion of this activity, participants should be better able to: Outline the current unmet treatment needs for patients with advanced melanoma; Review the mechanism of action of anti–LAG-3/PD-1 combinations for the management of advanced melanoma; and Recognize the clinical impact of approved and emerging anti–LAG-3/PD-1 combinations as a therapeutic strategy for the treatment of advanced melanoma.